Press Releases April 7, 2026 08:00 PM

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Aclaris Therapeutics to Present at H.C. Wainwright Inflammatory Skin Disease Conference

By Priya Menon ACRS
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
ACRS

Aclaris Therapeutics, a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, announced participation of its CEO and senior leadership in a fireside chat at the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026. The event will be webcast live and archived on the company's website.

Key Points

  • Aclaris Therapeutics is focused on developing novel treatments for immuno-inflammatory diseases with unmet medical needs.
  • The CEO and senior leadership will discuss company developments and outlook during the virtual conference fireside chat.
  • The conference participation provides an opportunity for the company to communicate directly with investors and stakeholders in the healthcare and biotech sectors.

WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
[email protected]


Risks

  • As a clinical-stage biopharmaceutical firm, Aclaris faces risks related to clinical trial outcomes and regulatory approvals, impacting biotechnology and pharmaceutical markets.
  • Market reception to the company's updates and progress may be uncertain, potentially influencing investor sentiment in the healthcare sector.
  • Dependence on successful R&D and product development timelines presents operational risks inherent to the biopharmaceutical industry.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026